# A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease

> **NCT01958827** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 28 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Adalimumab

## Key facts

- **NCT ID:** NCT01958827
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-10
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2016-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958827, "A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01958827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*